文献速递胸部技术与安全MRPET

基于限制性谱成像和酰胺质子转移加权成像的多参数18F-FDG PET/MRI有助于评估非小细胞肺癌淋巴结转移

Multiparametric 18F-FDG PET/MRI based on restrictive spectrum imaging and amide proton transfer-weighted imaging facilitates the assessment of lymph node metastases in non-small cell lung cancer.
PubMed 文献 · Radiol Med · 2025-04-15

本研究纳入152例非小细胞肺癌患者,评估基于三室限制性谱成像、酰胺质子转移加权成像和弥散加权成像的多参数18F-FDG PET/MRI对淋巴结转移的诊断价值。淋巴结转移阳性组86例、阴性组66例。最大病灶直径、f1、MTRasym(3.5 ppm)、SUVmax和ADC为独立预测因子,联合诊断AUC为0.978,敏感度95.35%、特异度90.91%,显著高于各单一参数。

要点

  • 联合最大病灶直径、f1、MTRasym(3.5 ppm)、SUVmax和ADC诊断淋巴结转移的AUC达0.978。
  • 淋巴结转移阳性组MTRasym(3.5 ppm)、SUVmax、f2、f3高于阴性组,ADC和f1低于阴性组。
  • 联合诊断AUC显著高于最大病灶直径、f1、MTRasym(3.5 ppm)、SUVmax和ADC各单一参数。

核心结论

  • 基于RSI、APTWI和DWI的多参数18F-FDG PET/MRI有助于无创评估非小细胞肺癌的淋巴结转移状态。

研究设计与样本

  • 共纳入152例非小细胞肺癌患者(淋巴结转移阳性86例,阴性66例),行胸部多参数18F-FDG PET/MRI检查。

关键影像表现/征象

  • 淋巴结转移阳性组MTRasym(3.5 ppm)、SUVmax、f2和f3高于淋巴结转移阴性组(均P<0.05)。
  • 淋巴结转移阳性组ADC和f1低于淋巴结转移阴性组(均P<0.05)。

诊断标准与关键数值

  • 最大病灶直径、f1、MTRasym(3.5 ppm)、SUVmax和ADC为非小细胞肺癌患者淋巴结转移状态的独立预测因子。
  • 上述五者联合诊断AUC=0.978,敏感度=95.35%,特异度=90.91%。
  • 单一参数诊断AUC:最大病灶直径0.774、f1 0.810、MTRasym(3.5 ppm) 0.832、SUVmax 0.834、ADC 0.783,联合诊断均显著高于各单一参数(均P<0.01)。
  • 联合诊断在基于bootstrap(1000样本)的内部验证中AUC=0.968。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: To investigate the value of multiparametric 18F-FDG PET/MRI based on tri-compartmental restrictive spectrum imaging (RSI), amide proton transfer-weighted imaging (APTWI), and diffusion-weighted imaging (DWI) in the assessment of lymph node metastasis (LNM) of non-small cell lung cancer (NSCLC).

METHODS: A total of 152 patients (LNM-positive, 86 cases; LNM-negative, 66 cases) with NSCLC underwent chest multiparametric 18F-FDG PET/MRI were enrolled. 18F-FDG PET- derived parameter (SUVmax), RSI-derived parameters (f1, f2, and f3), APTWI-derived parameter (MTRasym(3.5 ppm)), DWI-derived parameter (ADC), and were calculated and compared. Logistic regression analysis was used to identify independent predictors, and combined diagnostics. Area under the receiver operating characteristic curve (AUC), calibration curves and decision curve analysis (DCA) were employed to assess the performance of the combined diagnostics.

RESULTS: MTRasym(3.5 ppm), SUVmax, f2, and f3 were higher and ADC and f1 were lower in LNM-positive group than in LNM-negative group (all P < 0.05). Maximum lesion diameter, f1, MTRasym(3.5 ppm), SUVmax, and ADC were independent predictors of LNM status in NSCLC patients, and the combination of them had an optimal diagnostic efficacy (AUC = 0.978; sensitivity = 95.35%; specificity = 90.91%), which was significantly higher than maximum lesion diameter, f1, MTRasym(3.5 ppm), SUVmax, and ADC (AUC = 0.774, 0.810, 0.832, 0.834, and 0.783, respectively, and all P < 0.01). The combined diagnosis showed a good performance (AUC = 0.968) in the bootstrap (1000 samples)-based internal validation. Calibration curves and DCA demonstrated that the combined diagnosis not only provided better stability, but also resulted in a higher net benefit for the patients involved.

CONCLUSION: Multiparametric 18F-FDG PET/MRI based on RSI, APTWI, and DWI is beneficial for the non-invasive assessment of LNM status in NSCLC.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Meng N, Liu X, Zhou Y, et al. Multiparametric 18F-FDG PET/MRI based on restrictive spectrum imaging and amide proton transfer-weighted imaging facilitates the assessment of lymph node metastases in non-small cell lung cancer. Radiol Med. 2025. PMID: 40232656. doi:10.1007/s11547-025-01992-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。